Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:08 PM
Study NCT ID:
NCT06038552
Status:
COMPLETED
Last Update Posted:
2023-09-15
First Post:
2023-09-05
Brief Title:
The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases
Sponsor:
First Affiliated Hospital Sun Yat-Sen University
Organization:
First Affiliated Hospital Sun Yat-Sen University
Study Overview
Official Title:
The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for Gastrointestinal Stromal Tumours Liver Metastasesa Retrospective Cohort Study
Status:
COMPLETED
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinibIM and IM alone in patients suffering from GIST liver metastases The main question it aims to answer is
Whether IM combined with hepatic resection HR or other local treatments such as radiofrequency ablation RFA and transarterial chemoembolization TACE has better long-term survival benefits compared to IM monotherapy
Patients are divided into different treatment groups
IM group
IM combined with HR group
IM combined with RFA or TACE group
Researchers will compare the IM HR group and IM RFATACE group with the IM group to see if it has a better Overall survival OS
Whether IM combined with hepatic resection HR or other local treatments such as radiofrequency ablation RFA and transarterial chemoembolization TACE has better long-term survival benefits compared to IM monotherapy
Patients are divided into different treatment groups
IM group
IM combined with HR group
IM combined with RFA or TACE group
Researchers will compare the IM HR group and IM RFATACE group with the IM group to see if it has a better Overall survival OS
Detailed Description:
Gastrointestinal stromal tumors GISTs represent the most prevalent type of mesenchymal tumor within the gastrointestinal tract and the liver is the most common site of metastasis from GIST Imatinib IM has significantly enhanced clinical outcomes for patients with advanced disease Since its approval in February 2002 for treating metastatic or unresectable GISTs 38 of patients have shown a partial response while 136 have experienced disease progression within 1 to 3 months of IM administration Over half of the patients with metastases experienced disease progression within two years of IM treatment attributed to secondary drug resistance Few studies are comparing the survival benefits of different surgical modalities The investigators aimed to evaluate IM combined with hepatic resection HR or other local treatments such as radiofrequency ablation RFA and transarterial chemoembolization TACE compared to IM monotherapy in long-term survival benefits in patients suffering from GIST liver metastases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None